Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zalunfiban
- Development stage
- Phase 3
- Lead developer
- CeleCor Therapeutics
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Zalunfiban is a next-generation, investigational small molecule glycoprotein IIb/IIIa (αIIbβ3) receptor antagonist developed for rapid pre-hospital treatment of ST-elevation myocardial infarction (STEMI). It is designed for subcutaneous administration by first responders or emergency department staff, reaching maximal antiplatelet effect within 15 minutes and wearing off in less than two hours. Zalunfiban works by locking the αIIbβ3 receptor in its inactive conformation through displacement of magnesium from the MIDAS site on the β3 subunit, thereby preventing platelet aggregation and clot formation. Its short duration of action aims to reduce bleeding risk and allow timely cardiac surgery if needed. Zalunfiban is currently being evaluated in phase 3 clinical trials for STEMI[1][2][4][5][6][8].
- Brand names
- Disaggpro
- Other names
- zalunfiban
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)
Beyond the preview
Go deeper on zalunfiban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zalunfiban.